# An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

> **NCT02937168** · PHASE4 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Reslizumab
- **DRUG:** Fludeoxyglucose F 18 (FDG)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02937168
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-08
- **Primary completion:** 2017-05-24
- **Final completion:** 2017-05-24
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937168, "An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02937168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*